StemCyte International (TPE:4178) Total Operating Expense: NT$339.3 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4178 StemCyte International Ltd TPE:4178
7 GF Score
Price NT$18.40
! 4 Warning Signs
View Full Analysis

What is StemCyte International Total Operating Expense?

StemCyte International TPE:4178 -2.39% 7 Total Operating Expense is NT$339.3 Mil as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review.

StemCyte International's Total Operating Expense for the three months ended in Mar. 2026 was NT$81.8 Mil. StemCyte International's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was NT$339.3 Mil.

StemCyte International Total Operating Expense Related Terms

StemCyte International Total Operating Expense Historical Data

* Premium members only.

The historical data trend for StemCyte International's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International Total Operating Expense Chart

StemCyte International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
271.01 343.87 370.11 349.79

StemCyte International Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.26 81.14 84.69 91.70 81.79
TPE:4178
7GF Score
StemCyte International Ltd TPE:4178
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCyte International Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$339.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of NT$339.3 Mil mean?
StemCyte International (TPE:4178) has a Total Operating Expense of NT$339.3 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on StemCyte International and its competitors.
Is StemCyte International's Total Operating Expense too high?
StemCyte International's current Total Operating Expense is NT$339.3 Mil. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Total Operating Expense compare to VRTX and REGN?
StemCyte International's Total Operating Expense of NT$339.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on StemCyte International and its competitors. StemCyte International's current Total Operating Expense is NT$339.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Total Operating Expense of NT$339.3 Mil. The current Total Operating Expense is NT$339.3 Mil. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Total Operating Expense is NT$339.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemCyte International Business Description

Address Zhongxiao East Raod, 9th Floor-2, No. 508, Section 7, Nangang District, Taipei, TWN
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score

Get the complete analysis for TPE:4178

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.40
Price